^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) +
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (PSMA inhibitor, Beta radiation emitter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Clin Nucl Med
    Title:

    Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer

    Published date:
    02/20/2021
    Excerpt:
    We report the case of a 68-year-old man with ATM mutation-positive mCRPC who showed exceptional response to concomitant administration of enzalutamide with 177Lu-PSMA-617.
    DOI:
    10.1097/RLU.0000000000003541